Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNK | O75909 | 10/20 | 0.44 |
| ▸ | CDK9 | P50750 | 10/20 | 0.44 |
| ▸ | UCHL1 | P09936 | 2/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.38 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.36 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.34 |
| ▸ | PTPRB | P23467 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.32 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21757604 | 0.96 | CCNK (0.42) | CCNKCDK9UCHL1USP30GSTO1 | |
| SCHEMBL21757533 | 0.94 | CCNK (0.53) | CCNKCDK9UCHL1USP30CCNT1 | |
| SCHEMBL21747565 | 0.86 | CCNK (0.48) | CCNKCDK9USP30NPSR1FFAR2 | |
| SCHEMBL23125463 | 0.83 | GRM2 (0.39) | CCNKCDK9GSTO1CCNT1PTPRB | |
| SCHEMBL23125466 | 0.83 | KMT2A (0.45) | GSTO1CCNT1PTPRBNPSR1FFAR2 | |
| SCHEMBL23125455 | 0.83 | CCNK (0.40) | CCNKCDK9UCHL1USP30CCNT1 | |
| SCHEMBL21747534 | 0.80 | CCNK (0.59) | CCNKCDK9CCNT1FFAR2 | |
| SCHEMBL21757531 | 0.79 | CDK9 (0.41) | CCNKCDK9CCNT1 | |
| SCHEMBL1439747 | 0.74 | CDK9 (0.38) | CCNKCDK9CCNT1CNR2 | |
| SCHEMBL23125459 | 0.73 | USP30 (0.43) | CCNKCDK9UCHL1USP30GSTO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3613737-B1 | NOVEL INHIBITOR OF CYCLIN-DEPENDENT KINASE CDK9 | GENFLEET THERAPEUTICS SHANGHAI INC (CN) | 2021-12-29 | — | — | EP | disclosed |
| US-10952999-B2 | Inhibitor of cyclin-dependent kinase CDK9 | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2021-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10952999-B2 | Inhibitor of cyclin-dependent kinase CDK9 | CDK9, CDK19, CDK1 | CCNK 14/4885CDK9 1/4885UCHL1 3034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.